Other Species / Isoforms
  TXA2-R (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S118-p
VMIFFGLsPLLLGAA
0 1
TXA2-R (human) VMIFFGLsPLLLGAA S118-p
TXA2-R iso2 (human) VMIFFGLSPLLLGAA S118
TXA2-R (mouse) AMVFFGLCPLLLGAA C117
TXA2-R (rat) AMVFFGLCPLLLGAA C117
S128-p
LLGAAMAsERYLGIT
0 1
TXA2-R (human) LLGAAMAsERYLGIT S128-p
TXA2-R iso2 (human) LLGAAMASERYLGIT S128
TXA2-R (mouse) LLGAAMASERFVGIT S127
TXA2-R (rat) LLGAAMAAERFVGIT A127
S145-p
FSRPAVAsQRRAWAT
Upstream
Downstream
2 0
Effects on Modified Protein
  • receptor desensitization, induced
Effects on Biological Processes:
  • signaling pathway regulation
Putative in vivo kinases:
  • PKCA (human)
Treatment
  • GF109203X
  • U46619
TXA2-R (human) FSRPAVAsQRRAWAT S145-p
TXA2-R iso2 (human) FSRPAVAsQRRAWAT S145-p
TXA2-R (mouse) PFSRPTATSRRAWAT T143
TXA2-R (rat) PFSRPAATSRRAWAT T143
G228
TLCHVYHGQEAAQQR
1 0
TXA2-R (human) TLCHVYHGQEAAQQR G228
TXA2-R iso2 (human) TLCHVYHGQEAAQQR G228
TXA2-R (mouse) TLCRVYHtREAtQRP T226-p
TXA2-R (rat) TLCRVYHAREATQRP A226
A232
VYHGQEAAQQRPRDS
1 0
TXA2-R (human) VYHGQEAAQQRPRDS A232
TXA2-R iso2 (human) VYHGQEAAQQRPRDs A232
TXA2-R (mouse) VYHtREAtQRPRDCE T230-p
TXA2-R (rat) VYHAREATQRPRDCE T230
S239
AQQRPRDSEVEMMAQ
1 0
TXA2-R (human) AQQRPRDSEVEMMAQ S239
TXA2-R iso2 (human) AQQRPRDsEVEMMAQ S239-p
TXA2-R (mouse) AtQRPRDCEVEMMVQ C236
TXA2-R (rat) ATQRPRDCEVEMMVQ C236
S324-p
RRLQPRLsTRPRsLs
Upstream
Downstream
2 0
Effects on Modified Protein
  • activity, inhibited
  • molecular association, regulation
Kinase, in vitro:
  • PKCA (human)
Putative in vivo kinases:
  • PKACA (human)
TXA2-R (human) RRLQPRLsTRPRsLs S324-p
TXA2-R iso2 (human) RRLQPRLSTRPRRsL S324
TXA2-R (mouse) RRLHPRFSsQLQAVs S321
TXA2-R (rat) RRLHPRFTSQLQAVS T321
T325
RLQPRLsTRPRsLsL
0 3
TXA2-R (human) RLQPRLsTRPRsLsL T325
TXA2-R iso2 (human) RLQPRLSTRPRRsLt T325
TXA2-R (mouse) RLHPRFSsQLQAVsL S322-p
TXA2-R (rat) RLHPRFTSQLQAVSL S322
S329-p
RLsTRPRsLsLQPQL
Upstream
Downstream
3 10
Effects on Modified Protein
  • receptor desensitization, altered
Kinase, in vitro:
  • PKCA (human)
Putative in vivo kinases:
  • PKACA (human)
Treatment
  • anti-CD3
  • nocodazole
TXA2-R (human) RLsTRPRsLsLQPQL S329-p
TXA2-R iso2 (human) gap -
TXA2-R (mouse) RFSsQLQAVsLRRPP A326
TXA2-R (rat) RFTSQLQAVSLHSPP A326
S331-p
sTRPRsLsLQPQLtQ
Upstream
Downstream
3 20
Effects on Modified Protein
  • activity, induced
  • molecular association, regulation
  • receptor desensitization, altered
  • receptor desensitization, induced
Effects on Biological Processes:
  • signaling pathway regulation
Kinase, in vitro:
  • PKCA (human)
Putative in vivo kinases:
  • PKACA (human)
  • PKG1 (human)
Treatment
  • anti-CD3
  • ischemia
  • KT5823
  • L-NAME
  • LY 83583
  • phorbol_ester
  • U46619
TXA2-R (human) sTRPRsLsLQPQLtQ S331-p
TXA2-R iso2 (human) gap -
TXA2-R (mouse) SsQLQAVsLRRPPAQ S328-p
TXA2-R (rat) TSQLQAVSLHSPPTQ S328
T337-p
LsLQPQLtQRSGLQ_
Upstream
Downstream
2 3
Effects on Modified Protein
  • receptor desensitization, altered
  • receptor desensitization, induced
Effects on Biological Processes:
  • signaling pathway regulation
Putative in vivo kinases:
  • PKCA (human)
Treatment
  • anti-CD3
  • dinoprost
  • GF109203X
  • PGE2
  • U46619
TXA2-R (human) LsLQPQLtQRSGLQ_ T337-p
TXA2-R iso2 (human) gap -
TXA2-R (mouse) gap -
TXA2-R (rat) gap -
-
gap
2 0
TXA2-R (human) gap -
TXA2-R iso2 (human) LSTRPRRsLtLWPSL S330-p
TXA2-R (mouse) gap -
TXA2-R (rat) gap -
-
gap
1 0
TXA2-R (human) gap -
TXA2-R iso2 (human) TRPRRsLtLWPSLEY T332-p
TXA2-R (mouse) gap -
TXA2-R (rat) gap -
-
gap
1 0
TXA2-R (human) gap -
TXA2-R iso2 (human) RLPGSSDsRASASRA S357-p
TXA2-R (mouse) gap -
TXA2-R (rat) gap -
-
gap
1 0
TXA2-R (human) gap -
TXA2-R iso2 (human) LLPFEPPtGKALSRK T399-p
TXA2-R (mouse) VsLRRPPAQAMLSGP A334
TXA2-R (rat) VSLHSPPTQAMLSGP T334